Andrew J. Roth

Articles

FALCON Trial Compares Two Types of Endocrine Therapy

December 19th 2013

The question of whether fulvestrant (Faslodex) should be moved forward in the treatment timeline for postmenopausal women with advanced, hormone receptor (HR)-positive breast cancer is being evaluated in an international, randomized phase III trial.

Lymphoseek Pursues Approval in Head and Neck Cancer

December 18th 2013

The FDA has granted a Fast Track designation to Lymphoseek (technetium Tc99m tilmanocept) as a radioactive diagnostic imaging agent for sentinel lymph node detection in patients with head and neck cancer.

Mammogram Study Provides Rationale for Expanding Screening Programs

December 5th 2013

Most deaths from breast cancer occur in women who have not been regularly screened and whose tumors are diagnosed at a median age 49 years, confirming the need for the greater use of annual mammography in younger women, according to a recent study that marks the latest episode in the debate over screening guidelines.

Burgeoning Field of Interventional Oncology Is Poised for Takeoff: A Q&A With Dan Brown, MD

December 5th 2013

Interventional oncology is an emerging field in cancer care that is intended to complement existing treatment modalities. We sat down with Dan Brown, MD, the new chief of Interventional Oncology at Vanderbilt University Medical Center, to discuss the burgeoning field and its potential effect on cancer care moving forward.

Early Data Show Patients With STS May Benefit From Belinostat

November 26th 2013

Final results from the first stage of the phase II portion of the phase I/II CLN-14 clinical trial analyzing belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas (STS) demonstrated that the novel agent could provide benefit in this space

Aldoxorubicin More Effective Than Doxorubicin in Soft Tissue Sarcomas

November 22nd 2013

Aldoxorubicin (formerly INNO-206) has demonstrated response rates that culminated in a higher incidence of stable disease when compared to doxorubicin as a first-line treatment for patients with advanced soft tissue sarcomas.

Large-Scale Analysis Confirms Superiority of Hyperfractionation in HNSCC

October 29th 2013

Hyperfractionated radiotherapy improved overall survival rates compared to standard and accelerated radiotherapy when administered without concomitant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma.

Vemurafenib Demonstrates Antitumor Activity in Papillary Thyroid Cancer

October 18th 2013

In a phase II clinical trial, the BRAF inhibitor vemurafenib demonstrated antitumor activity in patients with BRAFV600E-mutated papillary thyroid cancer who were either TKI treatment naÃ¯ve or had received prior TKI treatments.

Pooled Analysis Reinforces Long-Term Survival Benefit With Ipilimumab

October 2nd 2013

Results from a pooled analysis of data from 12 studies has demonstrated a long-term survival benefit that extends through at least 10 years for patients with advanced melanoma treated with ipilimumab.

Questions Remain Regarding Prognostic Value of BRAF Mutation in Papillary Thyroid Cancer

September 24th 2013

Several recently published papers have introduced contradicting findings on the usefulness of BRAF status for predicting the presence of aggressive papillary thyroid cancer.

High Levels of Cardiovascular Fitness Reduces the Risk of Developing and Dying From Cancer

May 15th 2013

Men with a high level of cardiovascular fitness at middle age had a reduced risk of developing and dying from lung and colorectal cancer later in life.

Men With High Risk of Skeletal Complications More Likely to Develop Fractures After ADT

January 21st 2013

Men with prostate cancer who had a high baseline risk of skeletal complications developed more fractures and had a higher mortality risk after long-term ADT when compared to men with lower baseline risk factors.

Supercomputer Network Allows for Faster Genomic Analysis

October 4th 2012

A new supercomputer-based network will allow physicians to transfer and analyze genomic data more rapidly than standard methods.

Tivantinib Study Halted Following Interim Analysis

October 3rd 2012

The phase III MARQUEE trial examining tivantinib has been halted following a planned interim analysis because it was not expected to meet its primary endpoint.

Updated BOLERO-2 Data Support Efficacy of Everolimus in Breast Cancer

September 20th 2012

Updated results from the BOLERO-2 trial support the study's earlier findings that mTOR kinase inhibitor everolimus improves survival for postmenopausal patients with breast cancer.

Study Supports Role for ALND in Early Breast Cancer

September 14th 2012

Patients with early-stage breast cancer at high risk of residual nodal disease might benefit from axillary lymph node dissection.